S
Sanjay Kaul
Researcher at Cedars-Sinai Medical Center
Publications - 222
Citations - 25862
Sanjay Kaul is an academic researcher from Cedars-Sinai Medical Center. The author has contributed to research in topics: Randomized controlled trial & Myocardial infarction. The author has an hindex of 67, co-authored 215 publications receiving 22556 citations. Previous affiliations of Sanjay Kaul include University of California, Los Angeles & Baylor University Medical Center.
Papers
More filters
Journal ArticleDOI
Understanding the Merits and Drawbacks of Noninferiority Trials in Cardiovascular Medicine.
TL;DR: Non-inferiority trials are typically performed when standard placebo-controlled trials are considered to be unethical or impractical and the new treatment offers advantages over the existing standard treatment in terms of safety, convenience, or cost as mentioned in this paper.
Journal ArticleDOI
Rosiglitazone and cardiovascular risk: nissen and wolski 2010 updated meta-analysis revisited
Sanjay Kaul,George A. Diamond +1 more
Journal ArticleDOI
Have the risks of rosiglitazone been exaggerated
Sanjay Kaul,George A. Diamond +1 more
TL;DR: A meta-analysis of clinical trials ignited a firestorm of controversy by claim-ing that treatment with rosiglitazone (Avandia, GlaxoSmithKline [GSK], a widely prescribed PPAR-γ agonist, was associated with a greater risk of myocardial infarc-tion and cardiovascular death.